首页> 美国卫生研究院文献>Annals of Laboratory Medicine >Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma Not Otherwise Specified
【2h】

Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma Not Otherwise Specified

机译:骨髓活检中含有超过20个CD3阳性细胞的簇是周围T细胞淋巴瘤的候选预后指标除非另有说明

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Assessment of bone marrow (BM) involvement in peripheral T-cell lymphoma, not otherwise specified (PTCL) is straightforward in cases of extensive involvement but difficult in cases of minimal to partial involvement. We evaluated the usefulness of CD3 as an immunohistochemical marker for assessing BM involvement in PTCL patients. BM biopsies of 92 PTCL patients were immunohistochemically stained for CD3, CD4, CD8, CD20, and CD56, and evaluated by two hematopathologists. CD3 positivity was graded according to the proportion of CD3-positive cells and the number of CD3-positive cells in a cluster. These criteria were used to determine the cut-offs at which significant differences in progression-free survival (PFS) and overall survival (OS) were observed. Multivariate analysis controlling the International Prognostic Index (IPI) score and its individual factors revealed that >20 CD3-positive cells in a cluster adversely affected PFS (relative risk [RR], 2.1; 95% confidence interval [CI], 1.0–4.3; P=0.047) and OS (RR, 2.4; 95% CI, 1.1–5.1; P=0.028) independent of IPI score. A cluster with >20 CD3-positive cells is a candidate indicator for BM involvement in PTCL.
机译:在广泛受累的情况下,对周围T细胞淋巴瘤(BMCL)的骨髓(BM)受累程度(未另作说明)的评估很简单,而对最小或部分受累则很难。我们评估了CD3作为免疫组化标记物评估PTCL患者中BM参与的有用性。对92例PTCL患者的BM活检进行了CD3,CD4,CD8,CD20和CD56免疫组织化学染色,并由两名血液病理学家进行了评估。根据群集中CD3阳性细胞的比例和CD3阳性细胞的数量对CD3阳性进行分级。这些标准用于确定观察到无进展生存期(PFS)和总体生存期(OS)显着差异的临界值。控制国际预后指数(IPI)分数及其各个因素的多变量分析显示,集群中> 20个CD3阳性细胞对PFS产生不利影响(相对风险[RR]为2.1; 95%置信区间[CI]为1.0-4.3; P = 0.047)和OS(RR,2.4; 95%CI,1.1-5.1; P = 0.028)与IPI得分无关。 CD20阳性细胞> 20的簇是BM参与PTCL的候选指标。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号